메뉴 건너뛰기




Volumn 22, Issue 2, 2015, Pages 123-132

Management of EGFR TKI–induced dermatologic adverse events

Author keywords

Acneiform rash; Adverse events; EGFR TKIS; Non small cell lung cancer; Paronychia; Stomatitis

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

EID: 84928267089     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2430     Document Type: Article
Times cited : (63)

References (65)
  • 1
    • 84891732343 scopus 로고    scopus 로고
    • Supportive care treatments for toxicities of antiegfr and other targeted agents
    • Melosky B. Supportive care treatments for toxicities of antiegfr and other targeted agents. Curr Oncol 2012;19(suppl 1):S59–63.
    • (2012) Curr Oncol , vol.19 , Issue.1 , pp. S59-S63
    • Melosky, B.1
  • 2
    • 79959295780 scopus 로고    scopus 로고
    • Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-smallcell lung cancer
    • Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-smallcell lung cancer. Curr Oncol 2011;18:126–38.
    • (2011) Curr Oncol , vol.18 , pp. 126-138
    • Hirsh, V.1
  • 3
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The ideal 1 trial)
    • [Erratum in: J Clin Oncol 2004;22:4863]
    • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 trial). J Clin Oncol 2003;21:2237–46. [Erratum in: J Clin Oncol 2004;22:4863]
    • (2003) J Clin Oncol , vol.21 , pp. 2237-2246
    • Ukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 4
    • 77950586775 scopus 로고    scopus 로고
    • The role of irreversible egfr inhibitors in the treatment of non-small cell lung cancer: Overcoming resistance to reversible egfr inhibitors
    • Belani CP. The role of irreversible egfr inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible egfr inhibitors. Cancer Invest 2010;28:413–23.
    • (2010) Cancer Invest , vol.28 , pp. 413-423
    • Belani, C.P.1
  • 5
    • 49149118719 scopus 로고    scopus 로고
    • BIBW2992, an irreversible egfr/her2 inhibitor highly effective in preclinical lung cancer models
    • Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible egfr/her2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702–11.
    • (2008) Oncogene , vol.27 , pp. 4702-4711
    • Li, D.1    Ambrogio, L.2    Shimamura, T.3
  • 6
    • 79960110757 scopus 로고    scopus 로고
    • Afatinib (BIBW 2992) development in non-small-cell lung cancer
    • Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011;7:817–25.
    • (2011) Future Oncol , vol.7 , pp. 817-825
    • Hirsh, V.1
  • 7
    • 84866255620 scopus 로고    scopus 로고
    • Randomized phase ii study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
    • Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase ii study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337–44.
    • (2012) J Clin Oncol , vol.30 , pp. 3337-3344
    • Ramalingam, S.S.1    Blackhall, F.2    Krzakowski, M.3
  • 8
    • 84928247084 scopus 로고    scopus 로고
    • United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci). Common Terminology Criteria for Adverse Events (CTCAE). Ver. 4. 03. Bethesda, MD: nci, cited April 29, 2012
    • United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute (nci). Common Terminology Criteria for Adverse Events (CTCAE). Ver. 4. 03. Bethesda, MD: nci; 2010. [Available online at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference:5x7.pdf; cited April 29, 2012]
    • (2010)
  • 9
    • 84984568870 scopus 로고    scopus 로고
    • On behalf of the mascc Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of egfr inhibitor–associated dermatologic toxicities
    • Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. On behalf of the mascc Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of egfr inhibitor–associated dermatologic toxicities. Support Care Cancer 2011;19:1079–95.
    • (2011) Support Care Cancer , vol.19 , pp. 1079-1095
    • Lacouture, M.E.1    Anadkat, M.J.2    Bensadoun, R.J.3
  • 10
    • 2342666031 scopus 로고    scopus 로고
    • Stomatitis: An overview: Protecting the oral cavity during cancer treatment
    • Brown CG, Yoder LH. Stomatitis: an overview: protecting the oral cavity during cancer treatment. Am J Nurs 2002;102(suppl 4):20–3.
    • (2002) Am J Nurs , vol.102 , Issue.4 , pp. 20-23
    • Brown, C.G.1    Yoder, L.H.2
  • 11
    • 66949133946 scopus 로고    scopus 로고
    • Clinical efficacy and toxicity of anti-egfr therapy in common cancers
    • Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-egfr therapy in common cancers. J Oncol 2009;2009:567486.
    • (2009) J Oncol , vol.2009
    • Harandi, A.1    Zaidi, A.S.2    Stocker, A.M.3    Laber, D.A.4
  • 12
    • 68349139865 scopus 로고    scopus 로고
    • Clinical significance of skin toxicity due to egfr-targeted therapies
    • Giovannini M, Gregorc V, Belli C, et al. Clinical significance of skin toxicity due to egfr-targeted therapies. J Oncol 2009;2009:849051.
    • (2009) J Oncol , vol.2009
    • Giovannini, M.1    Gregorc, V.2    Belli, C.3
  • 13
    • 20844448897 scopus 로고    scopus 로고
    • Her1/egfr inhibitor– associated rash: Future directions for management and investigation outcomes from the her1/egfr inhibitor rash management forum
    • Perez-Soler R, Delord JP, Halpern A, et al. her1/egfr inhibitor– associated rash: future directions for management and investigation outcomes from the her1/egfr inhibitor rash management forum. Oncologist 2005;10:345–56.
    • (2005) Oncologist , vol.10 , pp. 345-356
    • Perez-Soler, R.1    Delord, J.P.2    Halpern, A.3
  • 14
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
    • Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149–58.
    • (2003) JAMA , vol.290 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3
  • 15
    • 20044370274 scopus 로고    scopus 로고
    • Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
    • Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780–5.
    • (2005) Ann Oncol , vol.16 , pp. 780-785
    • Mohamed, M.K.1    Ramalingam, S.2    Lin, Y.3    Gooding, W.4    Belani, C.P.5
  • 16
    • 34447129570 scopus 로고    scopus 로고
    • Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase iii studies
    • Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase iii studies. Clin Cancer Res 2007;13:3913–21.
    • (2007) Clin Cancer Res , vol.13 , pp. 3913-3921
    • Wacker, B.1    Nagrani, T.2    Weinberg, J.3    Witt, K.4    Clark, G.5    Cagnoni, P.J.6
  • 17
    • 33646810076 scopus 로고    scopus 로고
    • The series clinic: An interdisciplinary approach to the management of toxicities of egfr inhibitors
    • Lacouture ME, Basti S, Patel J, Benson A 3rd. The series clinic: an interdisciplinary approach to the management of toxicities of egfr inhibitors. J Support Oncol 2006;4:236–8.
    • (2006) J Support Oncol , vol.4 , pp. 236-238
    • Lacouture, M.E.1    Basti, S.2    Patel, J.3    Benson, A.4
  • 18
    • 24944440830 scopus 로고    scopus 로고
    • On behalf of the tribute Investigator Group. Tribute: A phase iii trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    • Herbst RS, Prager D, Hermann R, et al. On behalf of the tribute Investigator Group. tribute: a phase iii trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892–9.
    • (2005) J Clin Oncol , vol.23 , pp. 5892-5899
    • Herbst, R.S.1    Prager, D.2    Hermann, R.3
  • 19
    • 22044445517 scopus 로고    scopus 로고
    • On behalf of the ncic Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. On behalf of the ncic Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues Pereira, J.2    Ciuleanu, T.3
  • 20
    • 34447262600 scopus 로고    scopus 로고
    • Phase ii study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
    • Cho BC, Im CK, Park MS, et al. Phase ii study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007;25:2528–33.
    • (2007) J Clin Oncol , vol.25 , pp. 2528-2533
    • Cho, B.C.1    Im, C.K.2    Park, M.S.3
  • 21
    • 34248140107 scopus 로고    scopus 로고
    • Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
    • Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545–52.
    • (2007) J Clin Oncol , vol.25 , pp. 1545-1552
    • Gatzemeier, U.1    Pluzanska, A.2    Szczesna, A.3
  • 22
    • 33947504732 scopus 로고    scopus 로고
    • Phase ii clinical trial of chemotherapy-naïve patients >or= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
    • Jackman DM, Yeap BY, Lindeman NI, et al. Phase ii clinical trial of chemotherapy-naïve patients >or= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760–6.
    • (2007) J Clin Oncol , vol.25 , pp. 760-766
    • Jackman, D.M.1    Yeap, B.Y.2    Lindeman, N.I.3
  • 23
    • 52449101985 scopus 로고    scopus 로고
    • A phase ii pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    • Felip E, Rojo F, Reck M, et al. A phase ii pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008;14:3867–74.
    • (2008) Clin Cancer Res , vol.14 , pp. 3867-3874
    • Felip, E.1    Rojo, F.2    Reck, M.3
  • 24
    • 39749087795 scopus 로고    scopus 로고
    • Randomized phase ii trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2
    • Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase ii trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863–9.
    • (2008) J Clin Oncol , vol.26 , pp. 863-869
    • Lilenbaum, R.1    Axelrod, R.2    Thomas, S.3
  • 25
    • 75249084998 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, phase ii study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
    • Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase ii study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080–7.
    • (2009) J Clin Oncol , vol.27 , pp. 5080-5087
    • Mok, T.S.1    Wu, Y.L.2    Yu, C.J.3
  • 26
    • 79959303941 scopus 로고    scopus 로고
    • Everolimus plus erlotinib versus erlotinib alone in previously treated patients withadvanced non-small cell lung cancer (Nsclc) [abstract 419P]
    • Bennouna J, Besse B, Leighl NB, et al. Everolimus plus erlotinib versus erlotinib alone in previously treated patients withadvanced non-small cell lung cancer (nsclc) [abstract 419P]. Ann Oncol 2010;21(suppl 8):viii140.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 140
    • Bennouna, J.1    Besse, B.2    Leighl, N.B.3
  • 27
    • 79959297851 scopus 로고    scopus 로고
    • Randomized phase ii study of sunitinib (Su) plus erlotinib (e) vs. Placebo (p) plus e for treatment of metastatic non-small cell lung cancer (nsclc) [abstract 417P]
    • Groen HJM, Socinski M, Grossi F, et al. Randomized phase ii study of sunitinib (su) plus erlotinib (e) vs. placebo (p) plus e for treatment of metastatic non-small cell lung cancer (nsclc) [abstract 417P]. Ann Oncol 2010;21(suppl 8):viii139.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 139
    • Groen, H.1    Socinski, M.2    Grossi, F.3
  • 28
    • 79959307493 scopus 로고    scopus 로고
    • Randomized phase iib study of pralatrexate vs. Erlotinib in patients with stage iiib/ iv non-small cell lung cancer (nsclc) after failure of prior platinum-based therapy [abstract LBA17]
    • Kelly K, Azzoli CG, Patel JD, et al. Randomized phase iib study of pralatrexate vs. erlotinib in patients with stage iiib/ iv non-small cell lung cancer (nsclc) after failure of prior platinum-based therapy [abstract LBA17]. Ann Oncol 2010;21(suppl 8):viii8.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 8
    • Kelly, K.1    Azzoli, C.G.2    Patel, J.D.3
  • 29
    • 79551703579 scopus 로고    scopus 로고
    • Sunitinib (Su) in combination with erlotinib (e) for the treatment of advanced/ metastatic nonsmall cell lung cancer (nsclc): A phase iii study [abstract LBA6]
    • Scagliotti GV, Krzakowski MJ, Szczesna A. Sunitinib (su) in combination with erlotinib (e) for the treatment of advanced/ metastatic nonsmall cell lung cancer (nsclc): a phase iii study [abstract LBA6]. Ann Oncol 2010;21(suppl 8):viii3.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 3
    • Scagliotti, G.V.1    Krzakowski, M.J.2    Szczesna, A.3
  • 30
    • 79959294024 scopus 로고    scopus 로고
    • A phase ii study of erlotinib plus capecitabine (Xel) as first line treatment for Asian elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study) [abstract 420P]
    • Zhao HY, Gongyan C, Feng J, et al. A phase ii study of erlotinib plus capecitabine (xel) as first line treatment for Asian elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study) [abstract 420P]. Ann Oncol 2010;21(suppl 8):viii140.
    • (2010) Ann Oncol , Issue.8 , pp. 140
    • Zhao, H.Y.1    Gongyan, C.2    Feng, J.3
  • 31
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib versus chemotherapy as first-line treatment for patients with advanced egfr mutation-positive non-small-cell lung cancer (Optimal, ctong-0802): A multicentre, open-label, randomised, phase 3 study
    • Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced egfr mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735–42.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 32
    • 79952748468 scopus 로고    scopus 로고
    • Phase iii trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer
    • Natale RB, Thongprasert S, Greco FA, et al. Phase iii trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:1059–66.
    • (2011) J Clin Oncol , vol.29 , pp. 1059-1066
    • Natale, R.B.1    Thongprasert, S.2    Greco, F.A.3
  • 33
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation–positive non-small-cell lung cancer (Eurtac): A multicentre, open-label, randomised phase 3 trial
    • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation–positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–46.
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 34
    • 84857501696 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (Titan): A randomised multicentre, open-label, phase 3 study
    • Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (titan): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300–8.
    • (2012) Lancet Oncol , vol.13 , pp. 300-308
    • Ciuleanu, T.1    Stelmakh, L.2    Cicenas, S.3
  • 35
    • 84883055532 scopus 로고    scopus 로고
    • On behalf of the tailor trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type egfr tumours (tailor): A randomised controlled trial
    • Garassino MC, Martelli O, Broggini M, et al. On behalf of the tailor trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type egfr tumours (tailor): a randomised controlled trial. Lancet Oncol 2013;14:981–8.
    • (2013) Lancet Oncol , vol.14 , pp. 981-988
    • Garassino, M.C.1    Martelli, O.2    Broggini, M.3
  • 36
    • 84868192444 scopus 로고    scopus 로고
    • First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (Topical): A double-blind, placebo-controlled, phase 3 trial
    • Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (topical): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012;13:1161–70.
    • (2012) Lancet Oncol , vol.13 , pp. 1161-1170
    • Lee, S.M.1    Khan, I.2    Upadhyay, S.3
  • 37
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase iii trial—intact 1
    • Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase iii trial—intact 1. J Clin Oncol 2004;22:777–84.
    • (2004) J Clin Oncol , vol.22 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3
  • 38
    • 1542713370 scopus 로고    scopus 로고
    • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase iii trial—intact 2
    • Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase iii trial—intact 2. J Clin Oncol 2004;22:785–94.
    • (2004) J Clin Oncol , vol.22 , pp. 785-794
    • Herbst, R.S.1    Giaccone, G.2    Schiller, J.H.3
  • 39
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37.
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3
  • 40
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (Interest): A randomised phase iii trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372:1809–18.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 41
    • 65549154268 scopus 로고    scopus 로고
    • Randomized phase ii study of gefitinib compared with placebo in chemotherapynaive patients with advanced non-small-cell lung cancer and poor performance status
    • Goss G, Ferry D, Wierzbicki R, et al. Randomized phase ii study of gefitinib compared with placebo in chemotherapynaive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253–60.
    • (2009) J Clin Oncol , vol.27 , pp. 2253-2260
    • Goss, G.1    Ferry, D.2    Wierzbicki, R.3
  • 42
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin– paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin– paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 43
    • 79956201837 scopus 로고    scopus 로고
    • A double-blind, randomized, placebo-controlled phase iii study of gefitinib (G) versus placebo (p) in patients (pts) with advanced nsclc, nonprogressing after first-line platinum-based chemotherapy (eortc 08021-ilcp)
    • Surmont VF, Gaafar RM, Scagliotti GV, et al. A double-blind, randomized, placebo-controlled phase iii study of gefitinib (g) versus placebo (p) in patients (pts) with advanced nsclc, nonprogressing after first-line platinum-based chemotherapy (eortc 08021-ilcp). Ann Oncol 2010;21(suppl 8):viii124.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 124
    • Surmont, V.F.1    Gaafar, R.M.2    Scagliotti, G.V.3
  • 44
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (Wjtog3405): An open label, randomised phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121–8.
    • (2010) Lancet Oncol , vol.11 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3
  • 45
    • 84883050731 scopus 로고    scopus 로고
    • Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (Icogen): A randomised, double-blind phase 3 non-inferiority trial
    • Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (icogen): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953–61.
    • (2013) Lancet Oncol , vol.14 , pp. 953-961
    • Shi, Y.1    Zhang, L.2    Liu, X.3
  • 46
    • 84862785051 scopus 로고    scopus 로고
    • Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (Lux-Lung 1): A phase 2b/3 randomised trial
    • Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (lux-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528–38.
    • (2012) Lancet Oncol , vol.13 , pp. 528-538
    • Miller, V.A.1    Hirsh, V.2    Cadranel, J.3
  • 47
    • 84884618137 scopus 로고    scopus 로고
    • Lux-Lung 4: A phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both
    • Katakami N, Atagi S, Goto K, et al. lux-Lung 4: a phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335–41.
    • (2013) J Clin Oncol , vol.31 , pp. 3335-3341
    • Katakami, N.1    Atagi, S.2    Goto, K.3
  • 48
    • 84862819699 scopus 로고    scopus 로고
    • Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (Lux-Lung 2): A phase 2 trial
    • Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (lux-Lung 2): a phase 2 trial. Lancet Oncol 2012;13:539–48.
    • (2012) Lancet Oncol , vol.13 , pp. 539-548
    • Yang, J.C.1    Shih, J.Y.2    Su, W.C.3
  • 49
    • 84928247083 scopus 로고    scopus 로고
    • ClinicalTrials.gov. lux-Lung 5: afatinib plus weekly paclitaxel versus investigator’s choice of single agent chemotherapy following afatinib monotherapy in non-small cell lung cancer patients failing erlotinib or gefitinib [clinical trial record]. Bethesda, MD: ClinicalTrials.gov, cited September 30, 2014
    • ClinicalTrials.gov. lux-Lung 5: afatinib plus weekly paclitaxel versus investigator’s choice of single agent chemotherapy following afatinib monotherapy in non-small cell lung cancer patients failing erlotinib or gefitinib [clinical trial record]. Bethesda, MD: ClinicalTrials.gov; 2012. [Available at: http://clinicaltrials.gov/ct2/show/NCT01085136; cited September 30, 2014]
    • (2012)
  • 50
    • 84892997539 scopus 로고    scopus 로고
    • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring egfr mutations (Lux-Lung 6): An open-label, randomised phase 3 trial
    • Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring egfr mutations (lux-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213–22.
    • (2014) Lancet Oncol , vol.15 , pp. 213-222
    • Wu, Y.L.1    Zhou, C.2    Hu, C.P.3
  • 51
    • 84884736973 scopus 로고    scopus 로고
    • Phase iii study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with egfr mutations
    • Sequist LV, Yang JC, Yamamoto N, et al. Phase iii study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with egfr mutations. J Clin Oncol 2013;31:3327–34.
    • (2013) J Clin Oncol , vol.31 , pp. 3327-3334
    • Sequist, L.V.1    Yang, J.C.2    Yamamoto, N.3
  • 52
    • 71649091295 scopus 로고    scopus 로고
    • E fficacy a nd safety of PF-00299804 (PF299) in patients with advanced nsclc after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (e): A two-arm, phase ii trial [abstract 8063]
    • cited February 20, 2015
    • Janne PA, Reckamp K, Koczywas M, et al. E fficacy a nd safety of PF-00299804 (PF299) in patients with advanced nsclc after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (e): a two-arm, phase ii trial [abstract 8063]. J Clin Oncol 2009;27:15s. [Availableonline at: http://meetinglibrary.asco.org/content/32872-65; cited February 20, 2015]
    • (2009) J Clin Oncol , vol.27 , pp. 15
    • Janne, P.A.1    Reckamp, K.2    Koczywas, M.3
  • 53
    • 79960460262 scopus 로고    scopus 로고
    • E fficacy a nd s afety o f PF299804 as first-line treatment (Tx) of patients (pts) with advanced (adv) nsclc selected for activating mutation (mu) of epidermal growth factor receptor (egfr) [abstract LBA18]
    • Mok T, Spigel DR, Park K, et al. E fficacy a nd s afety o f PF299804 as first-line treatment (tx) of patients (pts) with advanced (adv) nsclc selected for activating mutation (mu) of epidermal growth factor receptor (egfr) [abstract LBA18]. Ann Oncol 2010;21(suppl 8):viii8.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 8
    • Mok, T.1    Spigel, D.R.2    Park, K.3
  • 54
    • 79959297453 scopus 로고    scopus 로고
    • First report of the safety, pharmacokinetics, and preliminary activity of PF299804 in Japanese patients (Pts) with advanced solid tumors [abstract 533P]
    • Takahashi T, Boku N, Murakami H, et al. First report of the safety, pharmacokinetics, and preliminary activity of PF299804 in Japanese patients (pts) with advanced solid tumors [abstract 533P]. Ann Oncol 2010;21(suppl 8):174.
    • (2010) Ann Oncol , vol.21 , Issue.8 , pp. 174
    • Takahashi, T.1    Boku, N.2    Murakami, H.3
  • 55
    • 84895731447 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (Egfr)–mediated adverse events (aes) in patients (pts) with EGFR mutation positive (EGFR M+) nonsmall cell lung cancer treated with afatinib [abstract 895]
    • Yang JCH, Sequist LV, O’Byrne KJ, et al. Epidermal growth factor receptor (egfr)–mediated adverse events (aes) in patients (pts) with EGFR mutation positive (EGFR M+) nonsmall cell lung cancer treated with afatinib [abstract 895]. Eur J Cancer 2013;49(suppl 2):.
    • (2013) Eur J Cancer , vol.49 , Issue.2
    • Yang, J.1    Sequist, L.V.2    O’byrne, K.J.3
  • 56
    • 84916203811 scopus 로고    scopus 로고
    • Comparative safety profile of afatinib in Asian and non-Asian patients with EGFR mutation-positive (EGFR M+) non-small cell lung cancer (nsclc) [abstract P3.11-023]
    • Sequist LV, Yang JCH, Yamamoto N, et al. Comparative safety profile of afatinib in Asian and non-Asian patients with EGFR mutation-positive (EGFR M+) non-small cell lung cancer (nsclc) [abstract P3.11-023]. J Thorac Oncol 2013;8(suppl 2):S1197.
    • (2013) J Thorac Oncol , vol.8 , Issue.2 , pp. 1197
    • Sequist, L.V.1    Yang, J.2    Yamamoto, N.3
  • 57
    • 84863982274 scopus 로고    scopus 로고
    • Management of cutaneous adverse events induced by anti-egfr (Epidermal growth factor receptor): A French interdisciplinary therapeutic algorithm
    • Reguiai Z, Bachet JB, Bachmeyer C, et al. Management of cutaneous adverse events induced by anti-egfr (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm. Support Care Cancer 2012;20:1395–404.
    • (2012) Support Care Cancer , vol.20 , pp. 1395-1404
    • Reguiai, Z.1    Bachet, J.B.2    Bachmeyer, C.3
  • 58
    • 80052456722 scopus 로고    scopus 로고
    • On behalf of the North Central Cancer Treatment Group. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (egfr) inhibitor–induced rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)
    • Jatoi A, Dakhil SR, Sloan JA, et al. On behalf of the North Central Cancer Treatment Group. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (egfr) inhibitor–induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer 2011;19:1601–7.
    • (2011) Support Care Cancer , vol.19 , pp. 1601-1607
    • Jatoi, A.1    Dakhil, S.R.2    Sloan, J.A.3
  • 59
    • 50249101750 scopus 로고    scopus 로고
    • Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    • Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847–53.
    • (2008) Cancer , vol.113 , pp. 847-853
    • Jatoi, A.1    Rowland, K.2    Sloan, J.A.3
  • 60
    • 84894463392 scopus 로고    scopus 로고
    • How do I manage a patient with aphthous ulcers?
    • Clark D. How do I manage a patient with aphthous ulcers? J Can Dent Assoc 2013;79:d48.
    • (2013) J Can Dent Assoc , vol.48-79
    • Clark, D.1
  • 61
    • 33847065066 scopus 로고    scopus 로고
    • Nail toxicity associated with epidermal growth factor receptor inhibitor therapy
    • Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007;56:460–5.
    • (2007) J am Acad Dermatol , vol.56 , pp. 460-465
    • Fox, L.P.1
  • 62
    • 35448972109 scopus 로고    scopus 로고
    • Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: A dermatology–oncology perspective
    • Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology–oncology perspective. Skin Therapy Lett 2007;12:1–5.
    • (2007) Skin Therapy Lett , vol.12 , pp. 1-5
    • Lacouture, M.E.1    Melosky, B.L.2
  • 63
    • 0035868980 scopus 로고    scopus 로고
    • Acute and chronic paronychia
    • Rockwell PG. Acute and chronic paronychia. Am Fam Physician 2001;63:1113–16.
    • (2001) Am Fam Physician , vol.63 , pp. 1113-1116
    • Rockwell, P.G.1
  • 64
    • 33846245846 scopus 로고    scopus 로고
    • Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management
    • Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317–26.
    • (2007) J am Acad Dermatol , vol.56 , pp. 317-326
    • Hu, J.C.1    Sadeghi, P.2    Pinter-Brown, L.C.3    Yashar, S.4    Chiu, M.W.5
  • 65
    • 84863424046 scopus 로고    scopus 로고
    • Semiology of skin toxicity associated with epidermal growth factor receptor (Egfr) inhibitors
    • Peuvrel L, Bachmeyer C, Reguiai Z, et al. Semiology of skin toxicity associated with epidermal growth factor receptor (egfr) inhibitors. Support Care Cancer 2012;20:909–21.
    • (2012) Support Care Cancer , vol.20 , pp. 909-921
    • Peuvrel, L.1    Bachmeyer, C.2    Reguiai, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.